Sharon Runge became the first Canadian to receive Lecanemab, a newly approved Alzheimer’s drug shown to slow disease progression by about 30%. The treatment may extend independent living, but high costs and lack of public funding limit access. Doctors emphasize early intervention and urge government support for equitable access nationwide.
We'll keep you updated on all new application updates and features!